Hedy Lamarr : From Extase to Wifi
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
2 days ago
- France 24
Golf course and trade talks: Donald Trump mixes business & politics in Scotland
00:52 25/07/2025 Zelensky seeks EU support while Ukraine struggles with corruption Europe 24/07/2025 EU-China ties hit 'inflection point' and calls climate chage 'a priority' Europe 24/07/2025 EU says China's links with Russia now 'determining factor' in ties Europe 24/07/2025 EU tariffs on chinese EVs strain trade and diplomatic ties with Beijing Economy 24/07/2025 Spain beats Germany in Women's Euro 2025 and will play England on Sunday Europe 24/07/2025 War in Ukraine : Russia agrees prisoner swap but no deal on ceaserfire Europe 20/07/2025 Zelensky offers to hold new talks for ceasefire Europe 19/07/2025 EU launches new sanctions against Russia for more effective oil price cap Europe 17/07/2025 EU proposes 'most ambitious ever' budget of two trillion euros Europe
France 24
3 days ago
- France 24
Macrons sue Candace Owens over claims that Brigitte Macron is a man
05:14 20/07/2025 Palais de la découverte: Scientists say this historic museum could be shut down France 20/07/2025 France: Winemakers exploring new markets in non-alcoholic sector France 20/07/2025 France: Duplomb law's pesticide provision triggers unprecedented debate France 19/07/2025 Fraud probe opened into Mbappe payments to police officers France 17/07/2025 Lebanese Abdallah held since 1984 for US, Israeli diplomat murders Middle East 17/07/2025 Paris Summer Festival celebrates 35 years with artistic revival France 16/07/2025 Scandalous" : Angry French react to PM's idea to cut holidays France 16/07/2025 'Inheritance unequally distributed': Advanced economies all experiencing 'great wealth transfer' Europe 14/07/2025 Fireworks, warplanes and axes: France celebrates Bastille Day France
France 24
4 days ago
- France 24
Pharma giant Roche sees income soar in first half
It also reported that four potentially "practice-changing" drugs -- to treat Alzheimer's, Parkinson's, haemophilia and an antibiotic to fight a drug-resistant bacteria strain -- had advanced to the final stage of clinical development. Net income jumped 17 percent to reach 7.8 billion Swiss francs ($9.85 billion), while the Basel-based group confirmed its full-year outlook. Its sales exceeded forecasts, rising four percent to 30.9 billion Swiss francs -- or a seven-percent hike excluding currency effects, the world leader in cancer treatments said in a statement. Roche has two branches: pharmaceuticals and diagnostics. Its pharmaceuticals division saw sales rise 10 percent, at constant exchange rates, to 24 billion francs, primarily thanks to five "growth driver" medicines, including for breast cancer and asthma, which achieved total sales of 10.6 billion francs. That was 1.7 billion more than during the first half of 2024. Sales in its diagnostics division, however, were flat at constant exchange rates, at 6.95 billion francs. "We received numerous important approvals and reported positive data in disease areas with high unmet medical need," said Roche chief executive Thomas Schinecker. "Over the past six months, we have made significant progress in our pipeline and advanced four potentially practice-changing therapies into the final phase of clinical development," he said. These are NXT007 in haemophilia A, trontinemab in Alzheimer's disease, prasinezumab in early-stage Parkinson's disease, and zosurabalpin, "a novel antibiotic that could become the first in over 50 years to tackle a type of bacteria that has become resistant to most other treatments". For the full year, Roche said it was still targeting mid-single-digit sales growth excluding currency effects, equivalent to around five percent growth. In April, Roche announced plans to invest $50 billion in the United States over the next five years, following in the footsteps of Swiss rival Novartis, with US President Donald Trump's tariff war fuelling uncertainty in the sector. The United States is a key market for the pharmaceutical industry, representing around half of sales in Roche's pharmaceutical division.
